GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Aptevo Therapeutics Inc (NAS:APVO) » Definitions » Days Payable

APVO (Aptevo Therapeutics) Days Payable : 0.00 (As of Sep. 2024)


View and export this data going back to 2016. Start your Free Trial

What is Aptevo Therapeutics Days Payable?

Aptevo Therapeutics's average Accounts Payable for the three months ended in Sep. 2024 was $3.63 Mil. Aptevo Therapeutics's Cost of Goods Sold for the three months ended in Sep. 2024 was $0.00 Mil.

The historical rank and industry rank for Aptevo Therapeutics's Days Payable or its related term are showing as below:

During the past 11 years, Aptevo Therapeutics's highest Days Payable was 535.48. The lowest was 247.29. And the median was 283.59.

APVO's Days Payable is not ranked *
in the Biotechnology industry.
Industry Median: 127.14
* Ranked among companies with meaningful Days Payable only.

Aptevo Therapeutics's Days Payable stayed the same from Sep. 2023 (0.00) to Sep. 2024 (0.00). stayed the same


Aptevo Therapeutics Days Payable Historical Data

The historical data trend for Aptevo Therapeutics's Days Payable can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Aptevo Therapeutics Days Payable Chart

Aptevo Therapeutics Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Days Payable
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

Aptevo Therapeutics Quarterly Data
Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24
Days Payable Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Aptevo Therapeutics's Days Payable

For the Biotechnology subindustry, Aptevo Therapeutics's Days Payable, along with its competitors' market caps and Days Payable data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Aptevo Therapeutics's Days Payable Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Aptevo Therapeutics's Days Payable distribution charts can be found below:

* The bar in red indicates where Aptevo Therapeutics's Days Payable falls into.



Aptevo Therapeutics Days Payable Calculation

Days Payable indicates the number of days that the account payable relative to cost of goods sold the company has. An increase of Days Payable may suggest that the company delays paying its suppliers.

Aptevo Therapeutics's Days Payable for the fiscal year that ended in Dec. 2023 is calculated as

Days Payable (A: Dec. 2023 )
=Average Accounts Payable /Cost of Goods Sold*Days in Period
=( (Accounts Payable (A: Dec. 2022 ) + Accounts Payable (A: Dec. 2023 )) / count ) / Cost of Goods Sold (A: Dec. 2023 )*Days in Period
=( (0 + 0) / 1 ) / 0*365
=0 / 0*365
=N/A

Aptevo Therapeutics's Days Payable for the quarter that ended in Sep. 2024 is calculated as:

Days Payable (Q: Sep. 2024 )
=Average Accounts Payable / Cost of Goods Sold*Days in Period
=( (Accounts Payable (Q: Jun. 2024 ) + Accounts Payable (Q: Sep. 2024 )) / count ) / Cost of Goods Sold (Q: Sep. 2024 )*Days in Period
=( (3.736 + 3.532) / 2 ) / 0*365 / 4
=3.634 / 0*365 / 4
=N/A

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Aptevo Therapeutics Days Payable Related Terms

Thank you for viewing the detailed overview of Aptevo Therapeutics's Days Payable provided by GuruFocus.com. Please click on the following links to see related term pages.


Aptevo Therapeutics Business Description

Traded in Other Exchanges
N/A
Address
2401 4th Avenue, Suite 1050, Seattle, WA, USA, 98121
Aptevo Therapeutics Inc is a clinical-stage, research and development biotechnology company focused on developing novel immunotherapeutic candidates for the treatment of different forms of cancer. Its clinical candidate, APVO436, and preclinical candidates, ALG.APV-527 and APVO603, were developed using ADAPTIR modular protein technology platform. The versatile and robust ADAPTIR and ADAPTIR-FLEX platforms are designed to generate monospecific, bispecific, and multi-specific antibody candidates that are capable of enhancing the human immune system against cancer cells.
Executives
Daphne Taylor officer: SVP, CFO 3303 MONTE VILLA PARKWAY, BOTHELL WA 98021
Kevin C Tang 10 percent owner 4747 EXECUTIVE DRIVE, SUITE 210, SAN DIEGO CA 92121
Soyoung Kwon officer: See Remarks APTEVO THERAPEUTICS INC., 2401 4TH AVENUE, SUITE 1050, SEATTLE WA 98121
Tang Capital Management Llc 10 percent owner 4747 EXECUTIVE DRIVE, SUITE 210, SAN DIEGO CA 92121
Tang Capital Partners Lp 10 percent owner 4747 EXECUTIVE DRIVE, SUITE 210, SAN DIEGO CA 92121
Randy Joe Maddux officer: Senior VP, Operations 2401 4TH AVENUE, SUITE #1050, SEATTLE WA 98121
Fuad El-hibri director 2273 RESEARCH BLVD, SUITE 400, ROCKVILLE MD 20850
Daniel Abdun-nabi director 400 PROFESSIONAL DRIVE, SUITE 400, GAITHERSBURG MD 20879
Marvin L White director, officer: President and CEO 2273 RESEARCH BLVD, SUITE 400, ROCKVILLE MD 20850
Barbara Lopez Kunz director 2401 4TH AVENUE, SUITE 1050, SEATTLE WA 98121
Zsolt Harsanyi director 2273 RESEARCH BLVD., SUITE 400, ROCKVILLE MD 20850
Grady Iii Grant director 2401 4TH AVENUE, SUITE 1050, SEATTLE WA 98121
Shawnte Mitchell officer: SVP, GC and Corporate Affairs 5959 HORTON STREET, SUITE 500, EMERYVILLE CA 94608
Michael Adelman officer: SVP, Commercial Operations 2401 4TH AVENUE, SUITE 1050, SEATTLE WA 98121
Jane A Gross officer: See Remarks 2401 4TH AVENUE, SUITE 1050, SEATTLE WA 98121

Aptevo Therapeutics Headlines

From GuruFocus